en

Sarcoma Cancer Awareness Month

Diagnosing sarcomas remains one of the most complex areas in pathology. As a rare and highly heterogeneous group of malignancies arising from connective tissues, sarcomas often require a multimodal diagnostic approach.

AmoyDx® HANDLE Breast Cancer NGS Panel

Available now

ZytoVision FISH & CISH probes: precision in every signal

Get ZytoVision's  probes straight from the manufacturer—faster access, direct support, same trusted quality.

ASI has officially joined the ZYTOMICS family

By combining ASI’s imaging and analysis solutions with ZYTOMICS’ reagents, automation and analytics, the companies aim at creating more integrated and scalable solutions for pathology and cytogenetics laboratories.

AmoyDx® HANDLE Insight NGS Panel

New AmoyDx® NGS assay for the classification of endometrial carcinomas

Movember

Immunohistochemical (IHC) diagnostics play an important role in the diagnosis of prostate cancer, particularly in differentiating between benign and malignant prostate diseases and in determining the type of tumor.

AmoyDx® FGFR1-4 NGS Panel

Out now! Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes

Breast Cancer Awareness Month

Breast cancer is one of the most common cancers in women worldwide. In Germany, every 8th woman is diagnosed with breast cancer. Until now, therapies have been based on the presence/absence of (hormone) receptors or the Her2 receptor in metastatic/non-metastatic breast cancer.

S3 guideline for prostate cancer was updated

In May 2024 the S3 guideline "Prostate Cancer" (version 7.0) was updated.
Products Topics IVDR-Certified Portfolio Experts to Experts Resources Corporate Profile Distribution Contact us Resources Area
Sustainability Privacy Imprint Corporate Profile Certificates Terms & Conditions of Purchase Terms and Conditions
© 2026 Zytomics

Please select your region

Selecting your region and language ensures you receive the corresponding product portfolio and contact details.

Country / Region

Language